logo
Plus   Neg
Share
Email

XFOR Prices Offering At $12/Shr

X4 Pharmaceuticals, Inc. (XFOR) plans to sell 3.66 million shares of its common stock at $12 per share. The gross proceeds from the offering are expected to be approximately $65.0 million. The offering is slated to close on or about November 29, 2019.

Cowen and Stifel are acting as joint book-running managers for this offering.

Canaccord Genuity and Oppenheimer & Co. are acting as lead managers, and H.C. Wainwright & Co. and Roth Capital Partners are acting as managers for the offering.

X4 Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases.

The lead drug candidate is Mavorixafor.

A pivotal Phase 3 clinical trial of Mavorixafor for the treatment of WHIM syndrome is underway. The 52-week trial is designed to enroll 18 to 28 subjects in
approximately 20 countries, followed by an open-label extension trial.

Mavorixafor is also being explored in other indications like Severe Congenital Neutropenia and advanced clear cell renal cell carcinoma. The Company is also in preparations to begin Phase 1b clinical trial of Mavorixafor in Waldenström's macroglobulinemia later this quarter.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Airbnb has introduced few new rules to control parties and nuisances amidst the backlash the service received after the Halloween shooting at an Airbnb rental in a San Francisco. San Francisco-based Airbnb said it is banning "open invite" parties at all of its accommodations. The company is also banning... The U.S. Food and Drug Administration has approved three generic versions of Novartis' Gilenya capsule for treating relapsing forms of multiple sclerosis. "Approving safe and effective generics so patients have more treatment options continues to be a priority for the FDA," said Janet Woodcock, director... Shares of Upscale furniture chain RH (RH) are on a tear, on the heels of an upbeat annual forecast. Today, the stock set a new all-time high of $239.88.The stock is up more than 20% from its Dec 3 opening price of $196.66, and currently trading at $237.8, and nearly three-times its 52-week low of $84.11....
RELATED NEWS
Follow RTT
>